The Short Seller Who Crushed Valeant Has Picked His Next Target
- The short seller who took down Valeant bets against TransDigm
- TransDigm’s Howley is among the best-paid CEOs in America
Valeant Short Seller Picks Next Target
This article is for subscribers only.
Andrew Left sure knows how to pick a fight.
A little more than a year after his improbable takedown of Wall Street darling Valeant Pharmaceuticals, the blustery short seller is at it again. And the head of Citron Research is using the same blueprint as he sets his sights on TransDigm and its founder and Chief Executive Officer Nicholas Howley.